The Weblog for News and Views on the Clinical Trials IndustryClinical Trials Today, Part of the Centerwatch Network
CenterWatch
Clinical Trials Today: The weblog for opinions, news, and views on the Clinical Trials Industry

« Fraudulent Study Broker Cherie Thibodeau Continues to Bilk Sites | Main | Type II Diabetes Drug Fails Primary Endpoint »

Kendle Raises $200 Million Through Convertible Senior Note Offering

Cincinnati, Ohio-based Kendle International has closed a $200 million offering of convertible senior notes, which would become due in 2012. The notes would be converted into a combination of cash and common stock.

Kendle stated it would use the majority of the proceeds (approximately $146 million) for repayment of debt and general corporate purposes, including “working capital and acquisitions or investments in businesses, products or technologies complementary to its own.”

Kendle also entered into convertible note hedge transactions, intended to reduce any dilution to the company’s shareholders upon future conversion of the notes. The offering is being handled by UBS Investment Bank. Kendle reported revenues of $373.94 million last year.

Comments

Post a comment

Comments are moderated, and will not appear on this weblog until the author has approved them.

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/t/trackback/697361/20213000

Listed below are links to weblogs that reference Kendle Raises $200 Million Through Convertible Senior Note Offering:

Site Identification Services Product and Service Providers Clinical Trial Results Drugs in Clinical Trials Professional Bookstore Advertising Opportunities